COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$1.89 loss in FY 2023)

Simply Wall St · 2d ago

COSCIENS Biopharma (TSE:CSCI) Full Year 2024 Results

Key Financial Results

  • Revenue: US$9.59m (up 34% from FY 2023).
  • Net loss: US$15.3m (loss widened by 339% from FY 2023).
  • US$5.93 loss per share (further deteriorated from US$1.89 loss in FY 2023).

CSCI Products In Clinical Trials

  • Phase I: 1.
  • Phase III: 1.
earnings-and-revenue-history
TSX:CSCI Earnings and Revenue History April 14th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

COSCIENS Biopharma shares are up 13% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with COSCIENS Biopharma (at least 4 which are concerning), and understanding these should be part of your investment process.